Literature DB >> 3040815

The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection.

J M Wishart.   

Abstract

Itraconazole in a new, orally active triazole, which is related to ketoconazole and which is active against dermatophytes and Candida and Cryptococcus organisms. It is more potent than ketoconazole, is better absorbed with food, and does not suppress testosterone or cortisol synthesis. In previous studies, daily 200 mg doses of itraconazole for 5 days cleared 80% of cases of pityriasis versicolor, and 90% of dermatophyte infections were cleared by daily 100 mg doses administered for 1 month. Twenty patients with superficial dermatophyte, Candida albicans, and pityriasis versicolor infections were treated with doses of 50 or 100 mg per day; in the first group of 10 patients, the drug was administered before breakfast and the other 10 patients were given their dose with breakfast. Itraconazole concentration was determined by high-performance liquid chromatography 3 hours after administration of first and last doses. Our findings showed that although treatment with 50-mg doses led to poorer results and lower plasma levels than 100-mg doses, taking the drug with breakfast gave much better results than taking it before.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3040815     DOI: 10.1016/s0190-9622(87)70194-7

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  8 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Effect of cyclodextrin on the pharmacology of antifungal oral azoles.

Authors:  J S Hostetler; L H Hanson; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

3.  Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers.

Authors:  J A Barone; B L Moskovitz; J Guarnieri; A E Hassell; J L Colaizzi; R H Bierman; L Jessen
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

Review 4.  Pharmacology of itraconazole.

Authors:  K De Beule; J Van Gestel
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

6.  Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis.

Authors:  H M Miyazaki; S Kohno; Y Miyazaki; K Mitsutake; K Tomono; M Kaku; H Koga; K Hara
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

Review 7.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

Review 8.  The dermatophytes.

Authors:  I Weitzman; R C Summerbell
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.